 |
 |
|
USE IN PREGNANCY
When used in pregnancy during the second and third trimesters, drugs that act directly on the renin-angiotensin system can cause injury and even death to the developing fetus. When pregnancy is detected, COZAAR and HYZAAR should be discontinued as soon as possible. See WARNINGS: Fetal/Neonatal Morbidity and Mortality. |
|
|
|
This site contains information intended only for healthcare professionals
of the United States, its territories, and Puerto Rico. |
| (Because of regulatory issues, this material has not been approved for the general public.) |
|
| Enter—Yes, I Am a Healthcare Professional |
|
| For non-US Healthcare Professionals, click here. |
|
| COZAAR and HYZAAR are registered trademarks of E.I. du Pont de Nemours and Company, Wilmington, Delaware, USA |
|
20550836(1)-05/05-COZ
|
|
